Sunshine Historical Income Statement

Stocks . USA . 
Stock . Sunshine Biopharma Warrant
SBFMW Stock  USD 0.28  0.08  22.22%   
Historical analysis of Sunshine Biopharma income statement accounts such as Selling General Administrative of 12.2 M, Selling And Marketing Expenses of 886.6 K, Total Other Income Expense Net of 637.3 K or Research Development of 2.2 M can show how well Sunshine Biopharma Warrant performed in making a profits. Evaluating Sunshine Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Sunshine Biopharma's future profits or losses.
Cash Flow   Balance Sheet     Income Statement
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Sunshine Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sunshine Biopharma is a good buy for the upcoming year.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

About Sunshine Income Statement Analysis

Sunshine Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Sunshine Biopharma shareholders. The income statement also shows Sunshine investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Balance Sheet
Statement
Details
Cash Flow
Statement
Details
Financial
Indicators
Details
Valuation
Indicators
Details

Sunshine Biopharma Income Statement Chart

At this time, Sunshine Biopharma's Net Interest Income is fairly stable compared to the past year. Cost Of Revenue is likely to climb to about 19 M in 2025, despite the fact that Operating Income is likely to grow to (4.1 M).
Ebitda  Income Tax Expense  Selling And Marketing Expenses  Discontinued Operations  Net Income Applicable To Common Shares  
Add Fundamental

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.
Most accounts from Sunshine Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Sunshine Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.At this time, Sunshine Biopharma's Net Interest Income is fairly stable compared to the past year. Cost Of Revenue is likely to climb to about 19 M in 2025, despite the fact that Operating Income is likely to grow to (4.1 M).
 2022 2023 2024 2025 (projected)
Other Operating Expenses13.0M28.9M33.2M34.9M
Interest Expense39.4K137.3K157.9K148.9K

Sunshine Biopharma income statement Correlations

Interest Expense
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Net Income
Income Tax Expense
Selling General Administrative
Selling And Marketing Expenses
Total Other Income Expense Net
Research Development
Depreciation And Amortization
Total Revenue
Gross Profit
Discontinued Operations
Net Interest Income
Net Income From Continuing Ops
Cost Of Revenue
Reconciled Depreciation
Interest Expense
-0.060.170.080.08-0.090.090.09-0.09-0.110.03-0.280.010.01-0.04-0.04-0.02-0.150.06-0.04-0.04
Other Operating Expenses
-0.06-0.68-0.22-0.210.98-0.2-0.23-0.010.970.650.30.980.670.990.99-0.570.96-0.890.990.89
Operating Income
0.17-0.680.830.82-0.80.820.83-0.02-0.82-0.46-0.15-0.67-0.42-0.56-0.570.59-0.780.9-0.55-0.37
Ebit
0.08-0.220.831.0-0.391.00.990.07-0.42-0.250.21-0.25-0.11-0.08-0.090.52-0.340.62-0.060.17
Ebitda
0.08-0.210.821.0-0.381.00.990.07-0.41-0.250.21-0.25-0.1-0.07-0.080.52-0.340.61-0.050.18
Total Operating Expenses
-0.090.98-0.8-0.39-0.38-0.37-0.40.01.00.640.280.970.650.940.95-0.610.98-0.940.940.82
Income Before Tax
0.09-0.20.821.01.0-0.371.00.01-0.41-0.270.23-0.24-0.11-0.06-0.070.5-0.330.6-0.040.18
Net Income
0.09-0.230.830.990.99-0.41.0-0.04-0.43-0.270.22-0.26-0.11-0.09-0.10.5-0.350.62-0.070.15
Income Tax Expense
-0.09-0.01-0.020.070.070.00.01-0.040.0-0.08-0.01-0.010.04-0.01-0.010.37-0.020.030.00.14
Selling General Administrative
-0.110.97-0.82-0.42-0.411.0-0.41-0.430.00.640.30.960.640.930.93-0.610.98-0.950.920.8
Selling And Marketing Expenses
0.030.65-0.46-0.25-0.250.64-0.27-0.27-0.080.64-0.070.610.340.640.64-0.650.61-0.620.620.45
Total Other Income Expense Net
-0.280.3-0.150.210.210.280.230.22-0.010.3-0.070.170.110.310.310.210.46-0.120.320.45
Research Development
0.010.98-0.67-0.25-0.250.97-0.24-0.26-0.010.960.610.170.670.970.97-0.60.92-0.90.970.86
Depreciation And Amortization
0.010.67-0.42-0.11-0.10.65-0.11-0.110.040.640.340.110.670.670.67-0.050.59-0.590.670.74
Total Revenue
-0.040.99-0.56-0.08-0.070.94-0.06-0.09-0.010.930.640.310.970.671.0-0.520.93-0.821.00.93
Gross Profit
-0.040.99-0.57-0.09-0.080.95-0.07-0.1-0.010.930.640.310.970.671.0-0.530.93-0.831.00.93
Discontinued Operations
-0.02-0.570.590.520.52-0.610.50.50.37-0.61-0.650.21-0.6-0.05-0.52-0.53-0.560.7-0.5-0.18
Net Interest Income
-0.150.96-0.78-0.34-0.340.98-0.33-0.35-0.020.980.610.460.920.590.930.93-0.56-0.910.920.81
Net Income From Continuing Ops
0.06-0.890.90.620.61-0.940.60.620.03-0.95-0.62-0.12-0.9-0.59-0.82-0.830.7-0.91-0.81-0.63
Cost Of Revenue
-0.040.99-0.55-0.06-0.050.94-0.04-0.070.00.920.620.320.970.671.01.0-0.50.92-0.810.94
Reconciled Depreciation
-0.040.89-0.370.170.180.820.180.150.140.80.450.450.860.740.930.93-0.180.81-0.630.94
Click cells to compare fundamentals

Sunshine Biopharma Account Relationship Matchups

High Positive Relationship

Ebitda
+ 1.0
Ebit
Income Before Tax
+ 1.0
Ebit
Income Before Tax
+ 1.0
Ebitda
Selling General Administrative
+ 1.0
Total Operating Expenses
Net Income
+ 1.0
Income Before Tax
Gross Profit
+ 1.0
Total Revenue

High Negative Relationship

Net Income From Continuing Ops
- 0.95
Selling General Administrative
Net Income From Continuing Ops
- 0.94
Total Operating Expenses
Net Income From Continuing Ops
- 0.91
Net Interest Income
Net Income From Continuing Ops
- 0.9
Research Development
Net Income From Continuing Ops
- 0.89
Other Operating Expenses
Net Income From Continuing Ops
- 0.83
Gross Profit

Sunshine Biopharma income statement Accounts

202020212022202320242025 (projected)
Interest Expense168.1K328.8K39.4K137.3K157.9K148.9K
Other Operating Expenses648.3K2.7M13.0M28.9M33.2M34.9M
Operating Income(576.9K)(2.4M)(8.7M)(4.8M)(4.3M)(4.1M)
Ebit(2.6M)(12.1M)(26.5M)(4.0M)(3.6M)(3.8M)
Ebitda(2.6M)(12.1M)(26.4M)(3.8M)(3.4M)(3.6M)
Total Operating Expenses622.4K2.6M10.4M13.1M15.1M15.8M
Income Before Tax(2.8M)(12.4M)(26.5M)(4.1M)(3.7M)(3.9M)
Net Income(897.7K)(12.8M)(26.7M)(4.5M)(4.1M)(4.3M)
Income Tax Expense(1.9M)328.8K233.3K395.2K355.6K207.0K
Selling General Administrative547.4K1.9M8.9M10.1M11.6M12.2M
Total Other Income Expense Net(2.2M)(10.0M)489.6K674.4K607.0K637.3K
Research Development60.9K672.2K811.9K1.9M2.1M2.2M
Depreciation And Amortization14.1K12.7K25.2K149.1K171.5K180.1K
Total Revenue71.4K228.4K4.3M24.1M27.7M29.1M
Gross Profit45.6K110.6K1.7M8.3M9.6M10.1M
Net Income Applicable To Common Shares(2.2M)(1.7M)(2.8M)(12.4M)(11.2M)(10.6M)
Net Interest Income(168.1K)(328.8K)479.2K602.3K692.6K727.3K
Net Income From Continuing Ops(2.8M)(12.4M)(26.7M)(26.8M)(24.1M)(22.9M)
Cost Of Revenue25.8K117.8K2.6M15.8M18.1M19.0M
Reconciled Depreciation14.1K12.7K25.2K125.8K144.6K151.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CRMSalesforce
CCitigroup
GMGeneral Motors

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY